maci
autologous cultured chondrocytes on porcine collagen membrane

MyCartilage Care®

Call us at **877-872-4643** with any questions

Dictation Roadmap: Considerations

Coverage, coding, and payment information is provided for informational purposes only and is subject to change. Nothing contained herein is intended, nor should it be construed, to suggest a guarantee of coverage or reimbursement for any product or service. Check with the individual insurance provider regarding coverage. Providers should exercise independent clinical judgment when selecting codes and submitting claims to reflect accurately the services rendered to individual patients.

Insurance authorization of MACI is most likely when the prescribing physician's dictation addresses all of the insurer's specific medical policy criteria for ACI treatment.

To see provider policies click here and select the patient provider from the list.

Note unique patient descriptors as related to insurer criteria (where applicable)

Age

- "The patient is skeletally mature with documented closure of growth plates."
- "The patient is too young for a knee replacement."

BMI >35

- "BMI due to high muscle mass."
- "The patient is on an alternative weight loss program as injury has limited the ability to exercise."

Symptoms unique to the case

- "The patient's disabling knee pain and swelling are limiting the ability to perform functional activities."
- "The patient is unable to participate in physical therapy requirement due to intractable pain."

Clarify your clinical findings

Note if the overall condition of the knee and the treatment plan for concomitant conditions

- "The knee is stable and intact, with fully functional menisci and ligaments, has normal joint space, and is in good alignment."
- "Alignment correction will be performed concomitantly with MACI to achieve knee stability."

Describe the lesion, location and size

- "The 1.5 cm x 1.5 cm full-thickness grade III lesion is isolated on the weight bearing surface of the femoral condyle."
- "The lesion is well contained with normal surrounding cartilage."

Explain your assessment and plan

If applicable, explain the patient's functional limitations:

- "The patient experiences loss of knee function that interferes with the ability to perform activities of daily living (i.e., walking, stair climbing) and/or employment."
- "The patient has experienced disabling localized pain of at least a 3/10 intensity for at least 3 months."

If applicable, describe the failure of previous treatments

- "After three months, the patient has failed to respond to:
  - non-operative treatments (NSAIDs, injections, etc.);
  - activity modification; and
  - physical therapy OR physician directed home exercise program."
- "The patient had an inadequate response to debridement."
- "The patient wishes to undergo MACI treatment for her cartilage damage due to continued pain and limitation of her functional activity."

If applicable, note that the patient has none of the following:

- Osteoarthritis or arthritis in joint
- Kissing lesions
- Current infections
- Allergy to gentamicin or materials of bovine origin
- History of cancer in the bones, cartilage, fat or muscle of the affected limb

Indicate the patient has provided consent for this treatment

- "The patient understands the risk and potential benefits associated with the ACI procedure and has realistic expectations."
- "The patient is willing to comply with weight bearing restrictions and rehabilitation requirements following the ACI procedure."

MyCartilage Care®

Take the next step

toward helping your patients reach their cartilage treatment goals

MyCartilageCare.com/approval | 1-877-872-4643

maci

autologous cultured chondrocytes on porcine collagen membrane

Indication

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.
Safety and effectiveness of MACI in patients over the age of 55 years have not been established.

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:

- Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
- Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
- Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
- Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:

- Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
- The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

VERICEL

MACI®, MyCartilageCare®, Vericel®, and the Vericel logo are registered trademarks of Vericel Corporation.
©2025 Vericel Corporation. All rights reserved. PP.US.MAC.0722 v4.0